| BIIB |
Report |
Total revenue |
BEAT |
pred ~$2.47B vs. cons $2.42B |
MEDIUM |
| BIIB |
Report |
Non-GAAP diluted EPS |
IN-LINE |
pred ~$2.98 vs. cons $2.98 |
MEDIUM |
| BIIB |
Report |
LEQEMBI global in-market sales |
BEAT |
pred ~$195M vs. cons $190M |
MEDIUM |
| BIIB |
Guide |
FY 2026 total revenue, inclusive of Apellis |
BETTER |
guide ~$9.75B vs. cons $9.70B (FY 2026) |
MEDIUM |
| BIIB |
Guide |
FY 2026 non-GAAP diluted EPS, inclusive of Apellis and updated business-development charges |
LOWER |
guide ~$10.75 vs. cons $11.40 (FY 2026) |
HIGH |
| BIIB |
Guide |
SYFOVRE plus EMPAVELI revenue growth |
BETTER |
guide ~17% vs. cons 16% (FY 2026) |
MEDIUM |
| BIIB |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.5% |
— |
MEDIUM |
| BIIB |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
A revenue beat of ~$2.47B vs. $2.42B and resilient LEQEMBI sales of ~$195M vs. $190M are likely outweighed by FY 2026 EPS guidance near ~$10.75 versus ~$11.40 consensus. The incremental Q3 acquired-IPR&D/upfront-charge burden and Apellis financing/integration math should drive out-period estimate reductions rather than a one-day reaction only. |
MEDIUM |